A Prospective Study Comparing the Efficacy of Early Administration of Terlipressin and Somatostatin for the Control of Acute Variceal Bleeding in Patients with Cirrhosis / 대한간학회지
The Korean Journal of Hepatology
; : 373-384, 2006.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-96796
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS:
Terlipressin and somatostatin decrease portal venous pressure and they are used for the treatment of variceal bleeding. However, only a few studies have compared the efficacy of these drugs in combination with other procedures for hemostasis. Therefore, we performed a prospective study to compare the efficacy of terlipressin and somatostatin for controlling acute variceal bleeding when used in combination with other procedures for hemostasis.METHODS:
A total of 98 patients, who presented with variceal bleeding from September 2003 to May 2005, were randomly divided into the somatostatin group or terlipressin group. We compared the 5-day failure rate (defined as failure to control bleeding, rebleeding or death within 5 days of admission) and the 6-week mortality. The prognostic factors for 5-day failure and 6-week mortality were also evaluated.RESULTS:
There were no differences in baseline characteristics between the two groups. The overall 5-day failure rate and the cumulative 6-week mortality were 16.3% and 15.8%, respectively. The five-day failure rate and the cumulative 6-week mortality were not significantly different between the somatostatin and terlipressin groups. Hepatocellular carcinoma, the baseline serum creatinine level and endoscopic treatment for hemostasis were the significant predictors of 5-day failure; the baseline serum creatinine level was the predictor of 6-week mortality.CONCLUSIONS:
Both somatostatin and terlipressin were effective and showed comparable efficacy for the control of the acute variceal bleeding in the setting of a combined therapeutic approach. The baseline serum creatinine level may be a significant predictor for patient failure at 5 days and the 6-week mortality.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
Cardiovascular Disease
/
Cirrhosis
/
Digestive System Diseases
/
Liver Cancer
Database:
WPRIM (Western Pacific)
Main subject:
Varicose Veins
/
Vasoconstrictor Agents
/
Lypressin
/
Somatostatin
/
Esophageal and Gastric Varices
/
Acute Disease
/
Multivariate Analysis
/
Hemostasis, Endoscopic
/
Carcinoma, Hepatocellular
/
Hemorrhage
Type of study:
Observational study
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
Korean
Journal:
The Korean Journal of Hepatology
Year:
2006
Document type:
Article